To comply with regulations, what must a physician discuss with a patient before prescribing Schedule II to V substances?

A physician must discuss the risks associated with medications before prescribing controlled substances, including those categorized as Schedule II to V. This requirement is rooted in the principles of informed consent, which mandate that patients have a clear understanding of the potential dangers linked to a medication they are prescribed. These risks may include adverse effects, dependency, and the possibility of overdose, especially pertinent for controlled substances that have a higher potential for abuse.

While discussing the cost of medications, side effects, and benefits can be important aspects of the prescribing process, the primary regulatory obligation focuses on ensuring that patients are fully informed about the risks involved. This approach not only protects patients' health but also adheres to legal and ethical standards in healthcare, facilitating informed decision-making about their treatment options. Therefore, a comprehensive discussion of the associated risks is crucial in the context of prescribing controlled substances.